BAT progresses COVID-19 candidate vaccine into Phase I human clinical trials

BAT progresses COVID-19 candidate vaccine into Phase I human clinical trials

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on email
Email
Share on print
Print
  • Investigational New Drug application approved by the FDA for COVID-19 candidate vaccine, allowing BAT to progress into a Phase I clinical trial in adult volunteers
  • Vaccine candidate created using innovative plant-based technology
  • Vaccines manufactured using BAT’s vaccine platform have the potential to be stable at room temperature which could offer significant advantages
  • Study demonstrates BAT’s commitment to delivering science and innovation that build A Better Tomorrow

NAIROBI, Kenya, December 16, 2020 -/ African Media Agency(AMA)/- BAT’s US Bio-tech arm, Kentucky BioProcessing (KBP) today announced plans to commence a Phase I, first-time-in-human study of its COVID-19 vaccine candidate following approval of its Investigational New Drug application by the U.S. Food and Drug Administration (FDA). Enrolment for the study is expected to begin shortly.

The COVID-19 vaccine candidate (KBP-COVID-19; NCT04473690) will become one of a number of potential vaccines to have progressed beyond pre-clinical testing. The study is designed to enroll a total of 180 healthy volunteers who will be divided into two age cohorts, age 18-49 and age 50-70. Each group will then be subdivided into low and high dose treatment groups (N~45) and randomised 2:1 to receive either the low dose (15 ÎŒg KBP-COVID-19 vaccine + 0.5 mg adjuvant) or placebo, or high dose (45 ÎŒg KBP-COVID-19 vaccine + 0.5 mg adjuvant) or placebo. Results from the study are expected mid-2021 and, if positive, would allow for continued progress into a Phase 2 study, subject to regulatory approval.

The candidate vaccine has been developed using KBP’s innovative fast-growing plant-based technology. This unique approach has a number of possible advantages, including the rapid production of the vaccine’s active ingredients in around 6-weeks, compared to several months using conventional methods. The candidate vaccine also has the potential to be stable at room temperature, which could be a significant advantage for healthcare systems and public health networks worldwide. If successful, the speed of production of the active ingredients has the potential to reduce the time between identifying new viruses and strains, and vaccine development and deployment to those who need it.

KBP is conducting and recently completed enrolment for a Phase I clinical study of its quadrivalent (four-strain) influenza vaccine candidate (KBP-V001; NCT04439695), which uses the same nicotiana benthamiana plant-based technology platform.

Dr David O’Reilly, BAT’s Director of Scientific Research said:

“Moving into human trials with both our COVID-19 and seasonal flu vaccine candidates is a significant milestone and reflects our considerable efforts to accelerate the development of our emerging biologicals portfolio. It is our unique plant-based vaccine technology, which acts as a fast, efficient host for the production of antigens for a variety of diseases, that has enabled us to make this progress and respond to the urgent global need for safe and effective treatments and vaccines.

With both vaccines reaching these important milestones, the science around tobacco plant-based vaccine development and the unique platform continue to gain momentum.

Beverley Spencer-Obatoyinbo, BAT Kenya’s Managing Director said:

“This is part of our ongoing commitment to innovation and science, which are fundamental to our business. As a company committed to building A Better Tomorrow, we are proud to play our part in the global fight against this virus and – hopefully – we can contribute to the solution.”

For queries, contact: Email: caroline_mavuti@bat.com / Visit our websites at www.bat.com / www.batkenya.com.

Notes to Editors
The COVID-19 candidate vaccine in development uses KBP’s proprietary, fast-growing plant technology which has several potential advantages over conventional vaccine production technology:

  • Tobacco plants cannot host pathogens which cause human disease
  • Production may be faster because the elements of the vaccine accumulate in tobacco plants quickly – 6 weeks in tobacco plants versus several months using conventional methods
  • The vaccine formulation being developed has potential to be stable at room temperature, unlike many other conventional vaccines which often require refrigeration


BAT/KBP’s candidate COVID-19 vaccine, KBP-COVID-19, is not currently approved or licensed for use anywhere in the world.

Forward Looking Statements

This communication contains certain forward-looking statements, including “forward-looking” statements made within the meaning of Section 21E of the United States Securities Exchange Act of 1934. These statements are often, but not always, made through the use of words or phrases such as “believe,” “anticipate,” “could,” “may,” “would,” “should,” “intend,” “plan,” “potential,” “predict,” “will,” “expect,” “estimate,” “project,” “positioned,” “strategy,” “outlook”, “target” and similar expressions. These include statements regarding our intentions, beliefs or current expectations concerning, amongst other things, our results of operations, financial condition, liquidity, prospects, growth, strategies and the economic and business circumstances occurring from time to time in the countries and markets in which the BAT Group operates.

All such forward-looking statements involve estimates and assumptions that are subject to risks, uncertainties and other factors that could cause actual future financial condition, performance and results to differ materially from the plans, goals, expectations and results expressed in the forward-looking statements and other financial and/or statistical data within this communication. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking statements are uncertainties related to the following: the impact of competition from illicit trade; the impact of adverse domestic or international legislation and regulation; changes in domestic or international tax laws and rates and the impact of an unfavourable ruling by a tax authority in a disputed area; adverse litigation and dispute outcomes and the effect of such outcomes on the BAT Group’s financial condition; changes or differences in domestic or international economic or political conditions; the impact of the COVID-19 pandemic; adverse decisions by domestic or international regulatory bodies; the impact of market size reduction and consumer down-trading; translational and transactional foreign exchange rate exposure; the impact of serious injury, illness or death in the workplace; the ability to maintain credit ratings and to fund the business under the current capital structure; the inability to develop, commercialise and rollout New Categories; and changes in the market position, businesses, financial condition, results of operations or prospects of the BAT Group.

It is believed that the expectations reflected in this communication are reasonable, but they may be affected by a wide range of variables that could cause actual results to differ materially from those currently anticipated. Past performance is no guide to future performance and persons needing advice should consult an independent financial adviser. The forward-looking statements reflect knowledge and information available at the date of preparation of this communication and BAT undertakes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise. Readers are cautioned not to place undue reliance on such forward-looking statements.

No statement in this communication is intended to be a profit forecast and no statement in this communication should be interpreted to mean that earnings per share of BAT for the current or future financial years would necessarily match or exceed the historical published earnings per share of BAT.

Additional information concerning these and other factors can be found in BAT’s filings with the U.S. Securities and Exchange Commission (“SEC”), including the Annual Report on Form 20-F filed on 26 March 2020 and Current Reports on Form 6-K, which may be obtained free of charge at the SEC’s website, http://www.sec.gov, and the Company’s Annual Reports, which may be obtained free of charge from the British American Tobacco website www.bat.com.

You might also enjoy

Subscribe To Our Newsletter

Get updates and learn from the best

Conférence de Presse en Ligne


Les frontiĂšres terrestres ne doivent pas constituer des obstacles Ă  la dissĂ©mination de votre message. GrĂące Ă  notre service de confĂ©rence de presse en ligne, nous vous offrons l’opportunitĂ© de vous rapprocher des mĂ©dias africains, chaque fois que vous en aurez besoin.​

Nos services comprennent:​

​

​

Digital Communications


Today, social networks constitute an organization’s first point of contact with a user and a potential customer. At first glance, you need to convince of the relevance and quality of your content to stimulate and motivate the user to go further. We create consistently inspiring online strategy to meet business objectives, engage stakeholders and enhance our client brand’s reputation internally and externally.​

 

Communication​ digitale


Les rĂ©seaux sociaux reprĂ©sentent aujourd’hui le premier point de contact d’une organisation avec un utilisateur et un client potentiel. Au premier coup d’Ɠil, vous devez le convaincre de la pertinence et de la qualitĂ© de votre contenu pour l’inciter Ă  aller plus loin. Nous crĂ©ons pour vous une stratĂ©gie de communication prĂ©cise et adaptĂ©e sur les rĂ©seaux sociaux pour atteindre les objectifs commerciaux, impliquer les parties prenantes et amĂ©liorer la rĂ©putation de votre marque en interne et en externe.​

Promotion​ d’Ă©vĂ©nements


Le succĂšs d’un Ă©vĂ©nement rĂ©side en moitiĂ© dans sa promotion. Peu importe la beautĂ© de l’évĂ©nement, la qualitĂ© des orateurs et de l’ordre du jour, si personne ne rapporte ou ne parle de votre Ă©vĂ©nement, vos efforts seront vains. Nous vous aidons Ă  façonner votre rĂ©cit et Ă  crĂ©er un engouement autour de votre Ă©vĂ©nement. De l’annonce de l’Ă©vĂ©nement Ă  la tenue de celui-ci, nous accompagnons votre effort de planification et le reflĂ©tons sur toutes les plateformes mĂ©diatiques.​

Formation​ MĂ©diatique


Nous fournissons Ă  vos porte-paroles les outils nĂ©cessaires pour prĂ©senter vos principaux messages et rĂ©pondre avec confiance et cohĂ©rence aux questions. Notre formation est organisĂ©e soit Ă  distance ou en prĂ©sentiel, avec des Ă©tudes de cas rĂ©els et des rĂ©pĂ©titions. Nos clients repartent avec le sentiment d’ĂȘtre Ă  l’aise devant les journalistes et d’agir en tant qu’ambassadeurs de la marque.​

Veille​ MĂ©diatique


Nous mesurons votre portĂ©e en relations publiques et rendons compte des informations de votre industrie et des activitĂ©s de vos  concurrents en surveillant la majoritĂ© des canaux de diffusion dans toute l’Afrique. Une veille mĂ©diatique complĂšte et opportune est essentielle pour s’assurer que vous ne manquez aucune rĂ©fĂ©rence Ă  votre marque, que vous ĂȘtes constamment informĂ© de ce qui se passe dans votre industrie et que vous ĂȘtes prĂȘt Ă  saisir les opportunitĂ©s et Ă  rĂ©duire les risques en temps opportun.​

Relations​ MĂ©dia


Peu importe le lieu oĂč ils se trouvent, nous sommes une source d‘informations fiables pour les journalistes qui Ă©crivent sur l’Afrique. Nous nous connaissons mutuellement et ils nous font confiance, car nous leur fournissons un contenu crĂ©dible qui les aide dans leurs tĂąches. Nous nous entretenons quotidiennement avec des journalistes aux quatre coins du continent, ce qui fait de nous l’un des organismes les plus efficaces pour mener des campagnes de relations avec les mĂ©dias.

Stratégie et développement de contenu


Nous crĂ©ons des stratĂ©gies de communication intelligentes, bien documentĂ©es et spĂ©cialisĂ©es destinĂ©es Ă  vous aider Ă  construire un rĂ©cit fort qui engagera votre audience. Nous travaillons en synergie avec vous afin de rĂ©diger des communiquĂ©s de presse et des articles d’opinions qui alimentent le rĂ©cit de votre entreprise. Notre Ă©quipe a une expĂ©rience approfondie dans la crĂ©ation de rĂ©cits et le dĂ©veloppement de contenu multimĂ©dia.

DIFFUSION DE COMMUNIQUES​ DE PRESSE​


C’est le service phare d’AMA. Nous avons mis en place des canaux de diffusion des communiquĂ©s de presse auprĂšs des journalistes des 54 États africains ainsi qu’auprĂšs des journalistes amĂ©ricains et europĂ©ens couvrant les sujets relatifs aux marchĂ©s Ă©mergents.​

​Nos services comprennent:​

​

​

Event Promotion


Half of the success of an event lays in its promotion. Doesn’t matter how beautiful the event is, how wonderful the speakers and the agenda are, if no one reports or talks about your event, your efforts are gone. We help you shape the narrative and create a drumbeat around your event. From the announce all the way to the outcome of the event, we accompany your planning effort and echo it through all media platforms

Media Training


We provide your spokespeople with the tools to present your key messages and answer questions with confidence and coherence. Our training is organised either remotely or face-to- face, with real case studies and rehearsals. Our clients leave feeling comfortable being in front of reporters and acting as brand ambassadors.

Media Monitoring


We measure and report on
your PR reach, industry news, and competitive activity by monitoring most channels in North, West, Central, East and Southern Africa. Comprehensive and timely media monitoring is critical to ensuring that you don’t miss any reporting of your brand,
you’re constantly informed on what’s going on around your business, and you’re ready to capitalise on opportunities and mitigate
risks in a timely fashion..

Media Relations


We have become an authoritative source of news for reporters writing about Africa, wherever they are. We know them, they know us, and they trust us for providing them with timely and accurate content that helps them do their job. We speak to reporters on a daily basis in all corners of the continent and this makes us one of the most effective agencies in running media relations campaigns.

Strategy & Content Development


We create smart and localised communications strategies to help build a strong narrative that will engage your audiences. We partner with you to create press releases and thought leadership pieces that sustain a drumbeat for your company’s narrative. Our team have deep experience in shaping narratives and developing media content.

PRESS RELEASE WIRE DISTRIBUTION

This is AMA’s flagship service. We have set up channels of distribution towards the journalists of the 54 African states, as well as to American journalists and European journalists covering emerging markets issues.
Our service includes:

Editorial advice

Localised editorial piece when needed

Distribution to the major print, broadcast and online publications along with industry-specific publications

Follow-up calls to secure interview request

Guaranteed distribution to Africa.com

Distribution to Bloomberg, LexisNexis and Thomson Reuters

Social Media Reach: Facebook, Twitter, LinkedIn, Instagram

Full online monitoring and print monitoring when available. Includesreadership stats and Advertising Value Equivalent

Translation in French, Arabic and Portuguese available